



# Thyroid Disease in Pregnancy: A 2022 Update

Angela M. Leung MD, MSc



@AngelaLeung9

University of California Los Angeles David Geffen School of Medicine  
Veterans Affairs Greater Los Angeles Healthcare System  
Los Angeles, California, U.S.A.



David Geffen  
School of Medicine



VA



U.S. Department  
of Veterans Affairs  
VA Greater Los Angeles Healthcare System

# Disclosures

- Co-Chair, planned update to the American Thyroid Association thyroid and pregnancy guidelines (in progress)
- Board of Directors, American Thyroid Association

# Learning Objectives

- Describe the changes in thyroid physiology that occur in pregnancy.
- Review the available evidence of the risks of maternal hypothyroidism and/or thyroid antibody positivity during pregnancy.
- Understand the challenges of the diagnostic workup and treatment of hyperthyroidism in pregnancy.
- Discuss the current understanding of the associations between pregnancy and thyroid cancer.
- Summarize the risks and benefits of longterm therapies for thyroid cancer during pregnancy.


# Outline

- Maternal hypothyroidism
- Maternal thyroid autoimmunity
- Maternal hyperthyroidism
- Thyroid nodules and thyroid cancer in pregnancy

# Outline

- **Maternal hypothyroidism**
- **Maternal thyroid autoimmunity**
- Maternal hyperthyroidism
- Thyroid nodules and thyroid cancer in pregnancy


# Deiodination of Thyroxine (T4)



# Most Circulating Thyroid Hormone is Protein-Bound

	% Distributions of Bound TH	% Free TH
T4-TBG	75	
T4-Albumin	10	0.03
T4-Transthyretin	15	
T3-TBG	75	
T3-Albumin	25	0.30

# Serum Thyroid Binding Globulin (TBG) Doubles During Pregnancy





# Reasons for Increased Maternal Thyroid Hormone Needs in Pregnancy

- Increased TBG concentrations (due to increased  $E_2$ )
  - Glycosylation leads to ↓ hepatic clearance
- Increased T3 and T4 inactivation by placental, fetal, and uterine D3
- Increased plasma volume of T4 distribution
- Placental transfer of T4 to the fetus (minimal amount)

The NEW ENGLAND JOURNAL of MEDICINE

## CLINICAL DECISIONS

INTERACTIVE AT NEJM.ORG

### Thyroid Function and Conception

*This interactive feature addresses the approach to a clinical issue. A case vignette is followed by specific options, neither of which can be considered either correct or incorrect. In short essays, experts in the field then argue for each of the options. Readers can participate in forming community opinion by choosing one of the options and, if they like, providing their reasons.*

#### CASE VIGNETTE

### A Woman Trying to Conceive

Angela X. Chen, M.B., B.S., M.P.H.

Ms. Thompson is a 31-year-old woman who has been trying to conceive for the past 12 months and comes to see you, her primary care physician. One month ago, she had a miscarriage at 7 weeks of gestation. She has not had any other pregnancies.

Ms. Thompson has always been healthy; she has no significant medical history. Her only regular medication is a prenatal multivitamin, which she has been taking regularly for the past 12 months. Before that, she had used the combined estrogen–progesterone oral contraceptive pill for several years. Since she discontinued the contraceptive pill, her menses have been regular, with a 28-day cycle.

Her family history is significant for autoim-

0.5 to 4.0) and the free thyroxine ( $T_4$ ) concentration is 1.1 ng per deciliter (14 pmol per liter; normal range, 0.86 to 1.9 ng per deciliter [11 to 24 pmol per liter]). However, the test for thyroid peroxidase antibodies is positive (78 IU per milliliter [normal range, <35]).

Ms. Thompson has read that changes in thyroid function can affect a woman's chances of having a successful pregnancy. Given the results of her tests, she is interested in your recommendation as to whether she should begin treatment with levothyroxine to increase her chances of conceiving.

#### TREATMENT OPTIONS

Which one of the following approaches would you take for this patient? Base your choice on the published literature, your own experience, published guidelines, and other information sources.

# A Case


- 31 year old woman, trying to conceive for the past year
- No significant medical history
- Only medication is a prenatal multivitamin
- One month ago:
  - Miscarriage at 7 weeks gestation
  - No prior pregnancies
- Family history significant for autoimmune disease
  - Brother: T1DM
  - Maternal uncle: Hashimoto's thyroiditis
- Serum TSH **3.2** (reference, 0.5-4.0), free T4 1.1 (reference, 0.86-1.9)
- Serum TPO Ab **78** IU/mL (normal, <35)

**Would you recommend starting levothyroxine?**

# How Common is Hypothyroidism in Pregnancy?

Region	Prevalence	n	TSH threshold	Reference
Maine, USA	2.2%	9,403	>6 mIU/L	Allan et al. <i>J Med Screen</i> 2000
Texas, USA	2.3%	25,756	>97.5 <sup>th</sup> percentile	Casey et al. <i>Obstet Gynecol</i> 2005
China	4.6%	8,012	Trimester-specific TSH result	Chen et al. <i>PLoS One</i> 2014
Spain	16.6%	2,509	Trimester-specific TSH result	Diguez et al. <i>Clin Endocrinol (Oxf)</i> 2014

# Subclinical Hypothyroidism (SCH) and Adverse Pregnancy Outcomes



# Consequences of Maternal Hypothyroidism During Pregnancy

## Obstetric Complications

- Miscarriage
- Placental abruption
- Preterm delivery


## Neonatal Complications

- Low birth weight / small for gestational age (SGA)
- Neonatal admissions to the NICU
- Neonatal respiratory distress syndrome
- Infant neurocognition
  - Verbal and nonverbal cognitive delays at 18-30 months
  - Decreased IQ at 7-9 years




Created by Oksana Latysheva  
from the Noun Project

# Obstetric Benefits of Treating Maternal Hypothyroidism




## Untreated maternal hypothyroidism:

- Relatively high rate of abortions and preterm deliveries
- Relatively low rate of term deliveries



## Correction of maternal hypothyroidism:

- Decreases prevalence spontaneous abortions and preterm deliveries
- Increases prevalence of term deliveries



# Importance of Normal Thyroid Function for Brain Development

<b>Prenatal neocortical neurogenesis <sup>1</sup></b>
<b>Growth of subventricular and subgranular zones <sup>2-5</sup></b>
<b>Cell migration in cerebral cortex, hippocampus, cerebellum <sup>6</sup></b>
<b>Axonal myelination <sup>7</sup></b>
<b>Axon and dendrite formation <sup>1</sup></b>
<b>Granule and other cerebellar cell proliferation; granule cell migration to intergeniculate leaflet; Purkinje cell maturation <sup>8</sup></b>
<b>Postnatal neurogenesis <sup>9</sup></b>

<sup>1</sup> Stenzel D et al. *Front Neuroanat* 2013

<sup>2</sup> DeSouza LA et al. *Mol Cell Neurosci* 2005

<sup>3</sup> Ambrogini P et al. *Neuroendocrinology* 2005

<sup>4</sup> Montero-Pedrazuela A et al. *Mol Psychiatry* 2006

<sup>5</sup> Lemkine GF et al. *FASEB J* 2005

<sup>6</sup> Auso E et al. *Endocrinology* 2004

<sup>7</sup> Noguchi T et al. *Neurochem* 1984

<sup>8</sup> Zoeller RT et al. *J Neuroendocrinol* 2004

<sup>9</sup> Ahmed OM et al. *Int J Dev Neurosci* 2008



# Haddow Study: Maternal Hypothyroidism and Childhood IQ

- Study cohort: >25,000 women with available banked sera
- There were 62 samples with maternal TSH >98%ile (~8-100 mIU/L), compared with 125 matched euthyroid controls
- Mother's offspring (7-9 yrs old) tested for 15 areas of intelligence, reading, attention, language, others

**Conclusion:** Children of hypothyroid mothers had **lower IQ (-4 points)** than controls


- The 48 children of untreated hypothyroid women had even lower IQ (-7 points) lower than controls

# Professional Society Recommendations for Thyroid Function Screening During Pregnancy


- Insufficient evidence for routine screening in pregnancy (ACOG, 2015)
- Universal screening in pregnancy (including in assisted reproduction) not recommended (AACE, 2012)
- Case-finding recommended only in high-risk pregnant women (Endocrine Society, 2012)
- Insufficient evidence to universal screening in preconception or pregnancy (ATA, 2017)
  - Exception is presence of risk factors



# Maternal Thyroid Antibodies and Spontaneous Miscarriage



# LT4 Benefits in Euthyroid TPOAb+ Pregnant Women



# TABLET Trial:

## Levothyroxine for Euthyroid TPO Ab(+) Women

- Double-blind placebo-controlled trial, 49 centers in the U.K.
- 50 mcg LT4 (n=952) versus placebo (n=476)

	LT4	Placebo	RR (95% CI)
Live birth $\geq$ 34 weeks GA	37.4%	37.9%	0.97 (0.83-1.14)
Pregnancy at 7 weeks GA	89.1%	90.5%	0.98 (0.93-1.04)
Miscarriage	28.2%	29.6%	0.95 (0.73-1.23)

**Conclusion:** Levothyroxine treatment in euthyroid TPO Ab(+) pregnant women did not improve birth rates and pregnancy outcomes compared to placebo

# CATS (Controlled Antenatal Thyroid Screening Study)



- Randomized trial of TFT screening in pregnant women before 15 weeks gestation
- Nearly 22,000 women in U.K. and Italy studied:
  - Sera either screened immediately or stored until after delivery
  - For abnormal screened results, LT4 initiated
- Childhood cognition tested at 3 years age

**Conclusion:** No difference in childhood IQ between screened and unscreened pregnant women

# When to Treat Hypothyroid Pregnant Women

- Treatment of **overt hypothyroidism** is recommended during pregnancy.
- Pregnant women with **TSH concentrations >2.5 mU/L** should be evaluated for TPO Ab status:

TPO Ab	TSH	Recommendation
TPO (+)	> 4.0 (1 <sup>st</sup> trimester) or > 5.0 (2 <sup>nd</sup> /3 <sup>rd</sup> trimesters)	Treat
TPO (-)	>10	Treat

# When to Treat Hypothyroid Pregnant Women

- Treatment of **overt hypothyroidism** is recommended during pregnancy.
- Pregnant women with **TSH concentrations >2.5 mU/L** should be evaluated for TPO Ab status:


TPO Ab	TSH	Recommendation
TPO (+)	> 4.0 (1 <sup>st</sup> trimester) or > 5.0 (2 <sup>nd</sup> /3 <sup>rd</sup> trimesters)	Treat
TPO (-)	>10	Treat
TPO (+)	2.5-4.0 (1 <sup>st</sup> trimester) or 2.5-5.0 (2 <sup>nd</sup> /3 <sup>rd</sup> trimesters)	Consider treatment
TPO (-)	4.0-10.0	Consider treatment
TPO (-)	< 4.0	No treatment



# Thyroid Hormone Replacement in Pregnancy


- The recommended treatment of maternal hypothyroidism is administration of **oral levothyroxine (LT4)**.
- Avoid any T3-containing preparations such as synthetic T3 or desiccated thyroid extract.
- Women with overt and subclinical hypothyroidism (treated or untreated) or those at risk for hypothyroidism:
  - Euthyroid but TPOAb-positive or TgAb-positive
  - Post-hemithyroidectomy
  - History of RAI receipt
- Monitor with serum TSH **every 4 weeks until midgestation** and **at least once near 30 weeks gestation**.

# Proportion of U.S. Prenatal Multivitamins Containing Iodine



**69%**  
(n=87)  
contain  
iodine

Non-prescription  
prenatal multivitamins  
(n = 127)



**28%**  
(n=27)  
contain  
iodine

Prescription prenatal  
multivitamins  
(n = 96)



## American Thyroid Association Recommendations for Iodine Intake during Preconception, Pregnancy, and Lactation

- All women during the preconception period, pregnancy, and lactation are advised to take an iodine-containing **prenatal MVI of 150 mcg daily**, preferably those derived from potassium iodide

# Outline

- Maternal hypothyroidism
- Maternal thyroid autoimmunity
- **Maternal hyperthyroidism**
- Thyroid nodules and thyroid cancer in pregnancy

# Goal Serum TSH Levels in Pregnancy

## First trimester:

bHCG

Lower limit	0.4 mIU/L lower than the lab's normal range
Upper limit	4.0 mIU/L if TPO (-) 2.5 mIU/L if TPO (+)


## Second and third trimesters:

Lower limit	Lab's normal range
Upper limit	Lab's normal range

# Challenges of a Decreased TSH in Early Pregnancy

- Medical history and physical examination are key
- Differential diagnosis:
  - Gestational thyrotoxicosis
  - New onset hyperthyroidism
- Radioiodine uptake are unable to be performed in pregnancy

# Serum Thyroid Function Tests During Pregnancy



- **hCG has a mild stimulatory effect on the TSH receptor in thyroid tissues**
- **Thus in the first trimester:**
  - **Mild increase of serum FT4 levels**
  - **TSH is inverse related to rising hCG levels**

# Persistent Risks of Treated Graves' Disease

Circulating TSI antibodies can remain positive several years later  
(remember in your pregnant patient)





# Anti-Thyroid Drug Associated Embryopathies


First identified in 1972 as choanal atresia (blockage of the rear nasal passage due to abnormal bony recanalization)



Hypothelia (absence of breast/nipples)



Broad nasal bridge  
Prominent epicanthic folds  
Short upslanting palpebral fissures  
Hypoplastic alae nasi (lateral nose atrophy)



High, broad nasal bridge  
Upward slanting palpebral fissures  
Micrognathia (mandibular hypoplasia)





Aplasia cutis (localized absence of skin)



Radioulnar synostosis  
(fusing of adjacent bones)

Wolf D et al. *Arch Otolaryngol Head Neck Surg* 2006;132(9):1009-1011.  
Abulezz TA, Shalkamy MA. *Indian J Plast Surg* 2009;42(2):261-264.  
Laurberg P, Andersen SL. *Thyroid* 2015;25(11):1185-1190.

# Autoimmunity Rebounds in the Postpartum Period



*PPTD=Postpartum thyroid dysfunction*

# Transfer of Thionamides to Infants via Breastmilk

	Propylthiouracil (PTU)	Methimazole (MMI) or Carbimazole (CM)
Amount transferred into breastmilk	0.025%	0.10-0.17% <b>(4-7x higher than PTU)</b>
Example	PTU 200 mg TID transfers ~0.149 mg daily to infant	Single MMI 40 mg dose transfers ~0.07 mg to infant
No known infant risks	Maternal doses <750 mg/day	Maternal doses <20 mg/day

Kampmann JP et al. *Lancet* 1980;1:736-737.

Johansen K et al. *Eur J Clin Pharmacol* 1982;23:339-341.

Hudzik B, Zubelewicz-Szkodzinska B. *Clin Endocrinol (Oxf)* 2016;85(6):827-830.

# Outline

- Maternal hypothyroidism
- Maternal thyroid autoimmunity
- Maternal hyperthyroidism
- **Thyroid nodules and thyroid cancer in pregnancy**

# Thyroid Nodules are Common in Pregnancy



- Overall thyroid nodule prevalence in pregnancy varies from **3-21%**
- At least 1/3 of all thyroid cancer patients are age <45 years (75% women)
- 11-20% of women with a nodule detected in the first trimester of pregnancy develop a second nodule in later pregnancy
- Thyroid nodule prevalence increases with parity:
  - 9.4% without prior pregnancy
  - 20.7% with one prior pregnancy
  - 20.7% with two prior pregnancies
  - 33.9% with  $\geq$ three prior pregnancies
- Positive association between increasing age & thyroid nodule prevalence during pregnancy

U.S. Surveillance, Epidemiology, and End Results (SEER) Program


Glinoe D, Soto MF, Bourdoux P, Lejeune B, Delange F, Lemone M, Kinthaert J, Robijn C, Grun JP, de Nayer P. Pregnancy in patients with mild thyroid abnormalities: maternal and neonatal repercussions. *J Clin Endocrinol Metab.* 1991 Aug;73(2):421-7.

Struve CW, Haupt S, Ohlen S. Influence of frequency of previous pregnancies on the prevalence of thyroid nodules in women without clinical evidence of thyroid disease. *Thyroid.* 1993 Spring;3(1):7-9.

# Potential Reasons for Pregnancy as a Thyroid Cancer Risk Factor

- Higher frequency of ER $\alpha$ (+) tumors in pregnancy, compared to post-partum
- Thyroid cancer can be stimulated by:
  - Estrogen-mediated growth
  - Stimulation of the MAPK pathway
  - Increased thyroglobulin expression
- hCG can mediate increased thyroid hormone and thyroglobulin levels

Section of PTC  
Diagnosed During Pregnancy:




Positive immunohistochemistry for  
estrogen receptor  $\alpha$

Vannucchi G, Perrino M, Rossi S, Colombo C, Vicentini L, Dazzi D, Beck-Peccoz P, Fugazzola L. Clinical and molecular features of differentiated thyroid cancer diagnosed during pregnancy. *Eur J Endocrinol.* 2010 Jan;162(1):145-51.


Messuti I, Corvisieri S, Bardesono F, Rapa I, Giorcelli J, Pellerito R, Volante M, Orlandi F. Impact of pregnancy on prognosis of differentiated thyroid cancer: clinical and molecular features. *Eur J Endocrinol.* 2014 Apr 10;170(5):659-66.

# Observation of Micropapillary Thyroid Cancers During Pregnancy



# Observation of Micropapillary Thyroid Cancers During Pregnancy

Patient #2









# History of Pregnancy is Not Associated with High-Risk Thyroid Cancer Features

N=1,204

California Cancer Registry (1999-2012)



Chen AC, Livhits MJ, Du L, Wu JX, Kuo EJ, Yeh MW, Leung AM. Recent Pregnancy Is Not Associated with High-Risk Pathological Features of Well-Differentiated Thyroid Cancer. *Thyroid*. 2018 Jan;28(1):68-71.

## 2017 American Thyroid Association Pregnancy Recommendations


“Pregnancy ***does not*** appear to pose a risk for tumor recurrence in women without structural or biochemical disease present prior to pregnancy.”

“However, for those who have a known structural or biochemical disease present at the time of conception, ***pregnancy may represent a stimulus to thyroid cancer growth*** and requires monitoring.”


# Risks vs. Benefits of TSH Suppression for DTC During Pregnancy

- Whether or not to suppress TSH (and target TSH level) **should be similar** to that of non-pregnant, non-lactating patients.
- Caution levothyroxine **overtreatment**.
- Lower TSH and/or higher FT4 levels in pregnancy have been associated with:
  - Preeclampsia
  - Small for gestational age newborns
  - Lower childhood IQ scores
  - Lower amount of cerebral gray mass in infants
- Possible benefits of TSH suppression (in lieu of immediate surgery during pregnancy) are unknown.

# RAI Ablation in Women is Associated with Delayed Childbirth



# Faster Decline of Ovarian Reserve After $^{131}\text{I}$ in Older Women



- Median elapsed time between RAI and final AMH measurement: 34 mos
- Median of 5 AMH levels obtained per woman

# Medullary Thyroid Cancers During Pregnancy

- **No available data** regarding:
  - Relative benefits of immediate vs delayed (post-delivery) surgery for MTC
  - Rate of MTC progression/recurrence during pregnancy in women with MTC
- If surgery is deferred, can consider **following MTC biomarkers**
  - Caveat: Calcitonin levels can rise 2-3 fold during pregnancy in post-thyroidectomy women, and remain high during breastfeeding
  - CEA levels not affected by pregnancy
- Both American and British guidelines **recommend surgery for WTC** during pregnancy, given the aggressiveness of these tumors

Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, Grobman WA, Laurberg P, Lazarus JH, Mandel SJ, Peeters RP, Sullivan S. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. *Thyroid*. 2017 Mar;27(3):315-389.

Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerrard Ba G, Gilbert J, Harrison B, Johnson SJ, Giles TE, Moss L, Lewington V, Newbold K, Taylor J, Thakker RV, Watkinson J, Williams GR, British Thyroid A. Guidelines for the management of thyroid cancer. *Clin Endocrinol (Oxf)* 2014; 81 Suppl 1:1-122.

# Anaplastic Thyroid Cancers During Pregnancy

- Lack of any human studies on ATC progression during pregnancy.
- Risks of ATC progression are likely outweighed by surgical risks.
- The ATA advises that **surgery for ATC should not be delayed until after delivery.**
- TKIs can be considered given the high morbidity/mortality of ATC.

# TKIs in Pregnancy are Class D

- Animal studies show associated teratogenicity and embryo toxicity.
- Case series have not reported any major obstetric complications and/or fetal anomalies.
- Currently TKIs are U.S. Food and Drug Administration Class D drugs
  - Possible human fetal risk
  - Potential benefits may warrant use of the drug in pregnant women despite potential risks



# Key Takeaway Points

- Thyroid hormone **requirements increase** in pregnancy
- Serum thyroid function and antibody **screening** during pregnancy is controversial
- Mild maternal hypothyroidism and/or positive thyroid antibodies may be associated with **adverse obstetric and childhood outcomes**
- **Trimester-specific TSH goals** should be targeted
- Graves' disease in pregnancy and lactation should be managed as conservatively as possible
- Pregnancy is **likely not a risk factor** for thyroid cancer development/progression but should be closely monitored



Thank You

[amleung@mednet.ucla.edu](mailto:amleung@mednet.ucla.edu)

